Tirzepatide is a dual GIP and GLP-1 receptor agonist injected once a week; Zepbound is the brand for weight loss and sleep apnea, and Mounjaro is the brand for type 2 diabetes.
Vial or KwikPen
The four-dose Zepbound KwikPen holds a month of treatment and launched on February 23, 2026 [6]. Single-dose vials need a syringe that measures 0.5 mL or 0.6 mL and a new syringe and needle for each dose [7]. On LillyDirect the two forms cost the same [1]. The Medicare GLP-1 Bridge covers the KwikPen and excludes vials and single-dose pens [2], so ask for the KwikPen if you plan to use Medicare.
Sponsored placement: open.
One local practice can be featured here. This is a paid, labeled placement and never an endorsement.
Feature your practice in Boca Raton, from $300 a month.
Practices pay to appear here. The listing is labeled as an ad and does not carry our recommendation.
Prices and savings cards
| Route | Price | Source |
|---|---|---|
| LillyDirect self-pay, 2.5 mg | $299 a month | [1] |
| LillyDirect self-pay, 7.5 to 15 mg, refilled within 45 days | $449 a month | [1] |
| Savings card, commercial plan covers Zepbound | As little as $25 | [8] |
| Medicare GLP-1 Bridge, KwikPen only | $50 a month | [9] |
At $449 a month, a year of Zepbound is $5,388, about 5.1% of Boca Raton's $106,273 median household income [4].
Mounjaro for type 2 diabetes
Mounjaro has the same active ingredient but is approved for type 2 diabetes in adults and children 10 and older [10]. Its list price is $1,112.16 for four pens [11]. With commercial coverage, its savings card can bring the cost to $25 [12]. See Mounjaro vs Zepbound.
Checking the prescriber and the product
Florida physicians are licensed by the Florida Board of Medicine [5]. FDA ended its tolerance of shortage-era tirzepatide compounding in March 2025 [13], and compounded tirzepatide is not FDA-approved or reviewed by FDA for safety, effectiveness or quality [14]. FDA has received more than 730 adverse event reports for compounded tirzepatide as of May 31, 2026 [14]. Read compounded tirzepatide.
Trial results
In SURMOUNT-1, 91% of people on 15 mg lost at least 5% of body weight and 57% lost at least 20%, compared with 35% and 3% on placebo [15]. Palm Beach County's adult obesity rate is 26.6% [3]. Nearby: Miami, Tampa and Orlando, or see where to get tirzepatide.
Label safety points
Stop and seek care for severe stomach pain that persists, a possible sign of pancreatitis [16]. Get help for swelling of the face or throat or trouble breathing. Using tirzepatide with insulin or a sulfonylurea raises the chance of low blood sugar. The boxed warning covers thyroid C-cell tumors; it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Stop Zepbound when pregnancy is recognized. Call 911 for emergencies.
Questions people ask
Does Medicare cover Zepbound vials?
No. The Medicare GLP-1 Bridge covers only the Zepbound KwikPen; single-dose vials and pens are excluded [2].
How much is Zepbound in Boca Raton?
LillyDirect self-pay is $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg when refilled within 45 days, checked Oct 17, 2026 [1].
Is the KwikPen more expensive than the vial?
No. LillyDirect lists the same self-pay prices for the Zepbound KwikPen and vials [1].
What is the Mounjaro list price?
Lilly lists Mounjaro at $1,112.16 for a 28-day supply of four pens [11].
How many people lost 20% of their weight on tirzepatide?
In SURMOUNT-1, 57% of people on the 15 mg dose lost at least 20% of body weight at 72 weeks, versus 3% on placebo [15].
Sources
16 cited
- Zepbound self-pay prices on LillyDirect. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
- Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, accessed 2026-10-17.
- PLACES data, county, 2025 release: Palm Beach County, FL. Centers for Disease Control and Prevention, 2025 release (2023 BRFSS).
- QuickFacts: Boca Raton city, Florida. U.S. Census Bureau, 2025 estimates and 2020-2024 ACS; accessed 2026-10-17.
- Florida Board of Medicine. Florida Department of Health, accessed 2026-10-17.
- Zepbound now available in multi-dose KwikPen. Eli Lilly and Company via PR Newswire, Feb 23, 2026.
- Zepbound label. DailyMed, National Library of Medicine, Aug 2026.
- Zepbound coverage and savings. Eli Lilly and Company, Oct 17, 2026.
- Weight loss drugs coverage (Medicare GLP-1 Bridge). Medicare.gov (CMS), accessed 2026-10-17.
- Mounjaro label. DailyMed, National Library of Medicine, Aug 2026.
- Mounjaro FAQ (list price and indications). Eli Lilly and Company, Oct 17, 2026.
- Mounjaro savings resources. Eli Lilly and Company, Oct 17, 2026.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, Apr 1, 2026.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine (PubMed), 2022.
- Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration, Apr 2026.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.